“Your baby has a 91% chance of having Down syndrome,” the genetic counselor told me over the phone. It was raining, and I was in the car, driving back home after having dropped my older son off at his aunt’s house for the day.
I was 15 weeks pregnant, and at the age of 37, mine was considered a “geriatric” pregnancy, so taking a non-invasive pre-natal test (NIPT) was standard procedure. The NIPT involved extracting and analyzing free-cell fetal DNA found in a sample of the mother’s blood. The test could give parents an idea of the likelihood of their child having an array of genetic disorders, with particular accuracy for identifying Down syndrome. Also known as Trisomy 21, DS occurs when an extra copy of the 21st chromosome develops during cell division. As an added bonus, the NIPT also gives parents the opportunity to learn the baby's gender much earlier than the standard 20-week anatomy ultrasound. I already had a two-year-old boy and was really hoping for a little girl to complete our family. A positive result for DS had been far from my mind.
As the NIPT is only a screening test, a diagnostic amniocentesis confirmed the results a few days later. I was having a baby boy with Down syndrome. At the time, I knew almost nothing about DS, having had only a few, transient encounters with individuals with DS up until this point. There had been a man with DS who would sometimes attend my childhood church, and I had watched Corky and his family on the show Life Goes On as a kid in the early 90s, but that was about as far as my knowledge of DS went.
After receiving the diagnosis, I was scared and nervous about what the future would hold for my baby. However, my protective maternal instincts kicked in, and I was determined to learn and do whatever was necessary to give him the best life possible. For the remaining months of my pregnancy, I drowned myself in information. I bought many books, Googled more than was probably healthy, and joined Facebook support groups filled with other moms raising kids with DS. I did my best to prepare for the unexpected and unknown.
When Oliver, or Ollie as we all call him, was born, it was love at first sight. He came a few weeks early via an unexpected c-section, but other than having to spend some time on the light bed for jaundice, he required no extra care and was a healthy and beautiful baby boy. I very quickly learned that his needs weren’t so “special.” Like all babies, diapers needed changing, food was a priority, and being held and cuddled was a preferred activity. Ollie showed me he would reach his milestones, just on his own schedule and at his own pace.
Parents and caregivers in the Down syndrome community like to refer to ourselves as, “The Lucky Few,” and, five years into our journey, I can say without a doubt that it’s a true statement. I feel extremely blessed and fortunate to be Ollie’s mom. Admittedly, it’s not all rainbows and unicorns, and there are extra challenges that come along with having that extra 21st chromosome. Due to a respiratory virus, we spent five weeks in the hospital when Ollie was 13 months old, of which 19 days were spent on a ventilator in the PICU. Every fall and winter for the next few years, we spent a few days to a couple weeks in the hospital due to more respiratory viruses. There’s a long list of specialists and therapists that we see regularly -- occupational therapy, gastroenterology, pulmonology, genetics, to name a few. There’s the stress of IEP meetings and the pressure of having to make decisions about the right kindergarten placement.
However, none of these stressors compare to the extra joy I experience every day being Ollie’s mom. His smile, laughter, and joy for life is infectious. He lights up whatever room he enters. Ollie has taught me to slow down and celebrate the small things. We sing and dance on a daily basis in our household. There are no small milestones – everything is celebrated! I’ve also discovered a wonderful, supportive community of fellow parents around the world that I know have my back should I ever need the support.
Not only have I felt supported by those in the DS community, but the support of my ICON family has also been an invaluable part of our journey. I feel blessed to work for a company that allows me the flexibility to attend appointments and care for my family without having to worry about the security of my job. I’ve been with ICON for almost 12 years now, and my loyalty is rooted in the trust that my team has in me to do my best at work, while also giving me the freedom to be my best for my family.
Facts about Down syndrome:
- World Down syndrome Day (WDSD) is celebrated on March 21st (3/21) because individuals with DS have three copies of the 21st chromosome. The day is often celebrated by wearing brightly colored or mismatched socks because chromosomes happen to look a little like socks.
- Down syndrome is the most common genetic disorder and occurs in approximately 1 out of every 700 births.
- Individuals with Down syndrome are more likely than the general population to have other health conditions, such as celiac disease, leukemia, Hirschsprung’s disease, congenital heart defects, Alzheimer’s disease, and speech and language impairments.
- While individuals with DS often have common characteristics, such as almond-shaped eyes, low muscle tone, and a mild to moderate intellectual disability, DS doesn’t affect every person the exact same way. Just like someone without a genetic condition, individuals with DS are each unique with their own strengths, challenges, and abilities.
- The future is limitless for someone with DS! Men and women with DS are Ironman athletes, models, actors, photographers, writers, fashion designers, bakers, and entrepreneurs!
In this section
-
Digital Disruption
-
Clinical strategies to optimise SaMD for treating mental health
-
Digital Disruption: Surveying the industry's evolving landscape
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Clinical strategies to optimise SaMD for treating mental health
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel